Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Opioid Policy topic
No spam. Unsubscribe anytime.
Senate opioid bill would create opioid‑free surgical opt‑out, prompt broad stakeholder talks
Summary
SB337 would create a legal pathway for patients to opt for opioid‑free or opioid‑sparing care for acute surgical pain, require patient education and insurer coverage for non‑opioid alternatives; sponsor expects amendments delaying effective date to allow implementation.
CARSON CITY — Senate Bill 337, authored by Senator Roberta Lang, would create a framework enabling patients to elect opioid‑free or opioid‑sparing surgical care and encourage insurer coverage of non‑opioid alternatives. Proponents said it is a prevention‑focused response to opioid addiction that often begins with legitimate prescriptions.
What the bill would do (as presented): SB337 seeks to require that patients be informed of opioid‑free alternatives and to create an advance directive permitting patients to opt out of opioids for acute post‑operative pain. Supporters also pushed for insurer coverage of some non‑opioid medications and modalities so clinicians and patients would have affordable alternatives.
Why advocates support it: Surgeons and clinicians who have implemented opioid‑sparing protocols said their outcomes show low post‑operative opioid use, faster return to work and fewer patients exposed to opioids. Testimony included clinicians reporting hundreds of opioid‑free procedures with only isolated patients using opioids afterward.
Key issues raised in committee
- Implementation: Hospital and insurer representatives said they need more time to implement changes; sponsors agreed to move the effective date to July 1, 2026, in response to those requests.
- Scope and evidence: Several senators asked for state‑level outcome data from states that have adopted similar models; proponents pointed to Michigan’s experience and early employer pilots showing reductions in opioid exposure among surgical patients.
- Regulation and liability: Stakeholders asked clarifying questions about whether the changes would require rulemaking, who would bear costs of new medications (some novel non‑opioid agents have high per‑pill prices) and how to ensure informed consent and clear provider/patient communication.
- Workforce and training: Representatives said hospitals and clinics will need time to educate clinicians and staff, and clarified that some provisions referencing nursing practice would be edited because current scope‑of‑practice rules differ by licensure.
Status and next steps: The sponsor signaled plans for technical amendments — including deleting language on nursing activities and updating an immunity provision to a specific NRS provision — and a delayed effective date to allow hospitals and insurers time to prepare. The hearing closed with broad stakeholder engagement and an agreement to continue negotiations on details before a work session vote.
Provenance
- Topic intro evidence: block_442 ("I will open the bill hearings for senate bill 3 3 7. This bill revises provisions relating to opioids...") - Topic finish evidence: block_697 ("Any closing remarks and move on to support testimony..." close of hearing)
